236 unknown, 136 recruiting, 130 completed, 53 not yet recruiting. 282 Phase 2, 139 Phase 3, 76 Phase 1, 71 Not applicable, 7 Early Phase 1.
Follow Nasopharyngeal Carcinoma: new trials by email Literature Review of Nasopharyngeal Carcinoma trials Research Report on Nasopharyngeal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-27 | 2026-10-22 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma BL-B01D1, PD-1 monoclonal antibody, Gemcitabine - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-16 |
| Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma reduced dose group, Standard Dose Group, concurrent chemoradiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Fudan University | 269 | 2026-09-01 | 2026-08-27 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors BL-M08D1 - Nasopharyngeal Carcinoma (NPC), Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-09-14 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Becotatug Vedotin - Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Kai Hu | 140 | 2026-09-01 | 2026-06-09 |
| Impacted Tooth Management and Osteoradionecrosis Risk in NPC Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction - Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw | Not applicable | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 536 | 2026-08-30 | 2026-08-14 |
| Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma (NPC), Myelosuppression | Recruiting | Nanfang Hospital, Southern Medical University | 1782 | 2026-08-26 | 2026-09-15 | |
| Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma Observation, Adjuvant therapy - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Fudan University | 148 | 2026-08-01 | 2026-08-13 |
| Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Recruiting | Hongmeng Yu | 25 | 2026-08-01 | 2026-08-24 |
| Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 48 | 2026-08-01 | 2026-07-16 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma Toripalimab combined with Nimotuzumab, Nimotuzumab - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 566 | 2026-07-20 | 2026-07-16 |
| A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma Proton Therapy System (ProBeam), Photon Therapy System (TrueBeam) - Nasopharyngeal Carcinoma (NPC) | Not applicable | Not yet recruiting | Guangzhou Concord Cancer Center | 504 | 2026-07-01 | 2026-07-08 |
| MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC MRG003, Tislelizumab, Capecitabine - Nasopharyngeal Carcinoma, Local Recurrence | Phase 2 | Recruiting | Fujian Cancer Hospital | 25 | 2026-06-16 | 2026-10-19 |
| Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers Acupuncture - Xerostomia, Head Cancer | Not applicable | Not yet recruiting | National University Hospital, Singapore | 50 | 2026-06-01 | 2026-06-29 |
Showing 20 of 645. Sign in to see all of them.
Nasopharyngeal Neoplasms (48) · Recurrence (27) · Squamous Cell Carcinoma of Head and Neck (27) · Head and Neck Neoplasms (25) · Neoplasm Metastasis (25) · Epstein-Barr Virus Infections (24) · Carcinoma, Non-Small-Cell Lung (13) · Carcinoma, Renal Cell (12) · Laryngeal Neoplasms (12) · Neoplasms (12) · Uterine Cervical Neoplasms (12) · Carcinoma (11) · Stomach Neoplasms (11) · Colorectal Neoplasms (10)
Neoplasms by Histologic Type (644) · Neoplasms by Site (644) · Neoplasms, Glandular and Epithelial (644) · Otorhinolaryngologic Neoplasms (644) · Pharyngeal Diseases (644) · Stomatognathic Diseases (644) · Otorhinolaryngologic Diseases (643) · Pharyngeal Neoplasms (643) · Nasopharyngeal Diseases (641) · Carcinoma (634) · Neoplasms (633) · Head and Neck Neoplasms (620) · Nasopharyngeal Neoplasms (597) · Pathological Conditions, Signs and Symptoms (63) · Pathologic Processes (58)
Cisplatin (131) · Gemcitabine (75) · Radiotherapy, Intensity-Modulated (61) · toripalimab (40) · Capecitabine (36) · Docetaxel (36) · Fluorouracil (35) · Radiotherapy (24) · camrelizumab (24) · Drug Therapy (22) · nimotuzumab (19) · spartalizumab (16) · pembrolizumab (14) · Chemoradiotherapy (13) · sintilimab (13)
Sun Yat-sen University (183) · Fudan University (26) · Zhejiang Cancer Hospital (21) · Fujian Cancer Hospital (18) · Jiangxi Provincial Cancer Hospital (14) · National Cancer Institute (NCI) (13) · Ming-Yuan Chen (10) · Eye & ENT Hospital of Fudan University (9) · Nanfang Hospital, Southern Medical University (9) · National University Hospital, Singapore (8) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (8) · Taichung Veterans General Hospital (8) · The University of Hong Kong (8) · First Affiliated Hospital of Guangxi Medical University (7) · Guangxi Medical University (7)
China (460) · United States (59) · Singapore (33) · Taiwan (30) · Hong Kong (18) · Canada (11) · Australia (8) · Malaysia (8) · South Korea (7) · France (6) · Italy (6) · Thailand (6) · Japan (4) · Spain (4) · Germany (3)
Jun Ma, M.D. (11) · Ming-Yuan Chen, MD,PhD (11) · Ming-Yuan Chen, MD, PhD (8) · Chaosu Hu, MD (6) · Jiade J Lu, MD (6) · Ming-yuan Chen, MD, PhD (5) · Chong Zhao, M.D (4) · Fang-Yun Xie, M.D. (4) · Jian Guan, Ph.D. (4) · Wei Jiang, Ph.D. (4) · Xiaozhong Chen (4) · Xiaozhong Chen, MD (4) · Yun-fei Xia, MD (4) · Brigette B Ma (3) · Chong Zhao (3)
PMID 31150573, PMID 30207593, PMID 27686945, PMID 28837405, PMID 29584545, PMID 34341578, PMID 30213452, PMID 31178151, PMID 33492986, PMID 35240053, PMID 35997729, PMID 36746459, PMID 38507662, PMID 39970442, PMID 19564532, PMID 22154591, PMID 30620929, PMID 34111416, PMID 34174189, PMID 34990291, PMID 35709465, PMID 37409613, PMID 37537541, PMID 37580352, PMID 37801967, PMID 38520712, PMID 40890288, PMID 41813900, PMID 42580817, PMID 10640954, PMID 10811668, PMID 11212235, PMID 11224527, PMID 14710949, PMID 14871955, PMID 15172975, PMID 15735118, PMID 15746043, PMID 15752890, PMID 15920746, PMID 15936155, PMID 16139912, PMID 16382236, PMID 16750333, PMID 18173375, PMID 19097774, PMID 20512145, PMID 21112774, PMID 21212426, PMID 21319149
P30CA138292 (3), U10CA180868 (3), 2019 (2), UM1CA186691 (2), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2025 (1), K24DC022077 (1), N01CM00099 (1), P01CA094237 (1), P30CA012197 (1), P30CA015704 (1), R01CA177996 (1)